Articles published by Pliant Therapeutics, Inc.

< Previous 1 2 3 Next >

Pliant Therapeutics Announces Presentations at the 2026 Annual Meeting of the Society for Immunotherapy of Cancer

October 29, 2026

From Pliant Therapeutics, Inc.

Via GlobeNewswire

Pliant Therapeutics Appoints Craig Blanchette, Ph.D., as Senior Vice President, Research (siRNA)

October 20, 2026

From Pliant Therapeutics, Inc.

Via GlobeNewswire

Pliant Therapeutics Announces Upcoming Presentation at European Society for Medical Oncology Congress 2026

October 19, 2026

From Pliant Therapeutics, Inc.

Via GlobeNewswire

Pliant Therapeutics Appoints David Raben, M.D., as Chief Medical Officer

September 30, 2026

From Pliant Therapeutics, Inc.

Via GlobeNewswire

Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors

August 18, 2026

From Pliant Therapeutics, Inc.

Via GlobeNewswire

Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

August 11, 2026

From Pliant Therapeutics, Inc.

Via GlobeNewswire

Pliant Therapeutics Names Flavia Borellini, Ph.D. and Robert Iannone, M.D., M.S.C.E. to Board of Directors

July 13, 2026

From Pliant Therapeutics, Inc.

Via GlobeNewswire

Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

May 21, 2026

From Pliant Therapeutics, Inc.

Via GlobeNewswire

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results

May 11, 2026

From Pliant Therapeutics, Inc.

Via GlobeNewswire

Pliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference

May 06, 2026

From Pliant Therapeutics, Inc.

Via GlobeNewswire

Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors

April 30, 2026

From Pliant Therapeutics, Inc.

Via GlobeNewswire

Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting

April 18, 2026

From Pliant Therapeutics, Inc.

Via GlobeNewswire

Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting

March 18, 2026

From Pliant Therapeutics, Inc.

Via GlobeNewswire

Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2025 Financial Results

March 11, 2026

From Pliant Therapeutics, Inc.

Via GlobeNewswire

Pliant Therapeutics to Participate in the Oppenheimer Healthcare Life Science Conference

February 23, 2026

From Pliant Therapeutics, Inc.

Via GlobeNewswire

Pliant Therapeutics Announces Interim Data from PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors

December 04, 2025

From Pliant Therapeutics, Inc.

Via GlobeNewswire

Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results

November 06, 2025

From Pliant Therapeutics, Inc.

Via GlobeNewswire

Pliant Therapeutics to Participate in the Piper Sandler Healthcare Conference

December 01, 2025

From Pliant Therapeutics, Inc.

Via GlobeNewswire

Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results

August 07, 2025

From Pliant Therapeutics, Inc.

Via GlobeNewswire

Pliant Therapeutics Provides Update on BEACON-IPF

June 27, 2025

From Pliant Therapeutics, Inc.

Via GlobeNewswire

Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference

May 21, 2025

From Pliant Therapeutics, Inc.

Via GlobeNewswire

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

May 08, 2025

From Pliant Therapeutics, Inc.

Via GlobeNewswire

Pliant Therapeutics Announces Strategic Realignment of Workforce and Operations

May 01, 2025

From Pliant Therapeutics, Inc.

Via GlobeNewswire

Pliant Therapeutics Announces Upcoming Presentations at the 2025 American Thoracic Society International Conference

April 07, 2025

From Pliant Therapeutics, Inc.

Via GlobeNewswire

Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors

March 17, 2025

From Pliant Therapeutics, Inc.

Via GlobeNewswire

Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement

March 13, 2025

From Pliant Therapeutics, Inc.

Via GlobeNewswire

Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2024 Financial Results

March 03, 2025

From Pliant Therapeutics, Inc.

Via GlobeNewswire

Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis

March 03, 2025

From Pliant Therapeutics, Inc.

Via GlobeNewswire

Pliant Therapeutics Announces Next Steps Following DSMB Recommendation on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis

February 13, 2025

From Pliant Therapeutics, Inc.

Via GlobeNewswire

Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis

February 07, 2025

From Pliant Therapeutics, Inc.

Via GlobeNewswire

< Previous 1 2 3 Next >

Articles published by Pliant Therapeutics, Inc.

Starting at /week.